There are limited studies targeting the ABCG2 gene for ovarian cancer, even though it is being studied clinically in other cancers; however, there is a correlation between ABCG2 upregulation and resistance to anthracyclines, such as doxorubicin. This evidence concerns the gene ABCG2 and ovarian carcinoma.